ASMB Aug 2024 2.000 call
| Previous close | 0.2800 |
| Open | 0.2500 |
| Bid | 0.0000 |
| Ask | 0.2500 |
| Strike | 2.00 |
| Expiry date | 2024-08-16 |
| Day's range | 0.2500 - 0.2800 |
| Contract range | N/A |
| Volume | |
| Open interest | 5 |
GlobeNewswireAssembly Biosciences to Present Data at Upcoming International Herpesvirus Workshop and EASL Congress™ 2024
-- Preclinical data from both ABI-5366 and ABI-1179, Assembly Bio’s long-acting helicase-primase inhibitor candidates targeting recurrent genital herpes, featured in poster and oral presentations at the International Herpesvirus Workshop -- -- Poster accepted for presentation at EASL Congress™ 2024 highlights preclinical profile of ABI-6250, a novel, small molecule orally-bioavailable entry inhibitor candidate for hepatitis D -- SOUTH SAN FRANCISCO, Calif., May 22, 2024 (GLOBE NEWSWIRE) -- Assem
ZacksAre Medical Stocks Lagging Entera Bio (ENTX) This Year?
Here is how Entera Bio Ltd. (ENTX) and Assembly Biosciences (ASMB) have performed compared to their sector so far this year.
- GlobeNewswire
Assembly Biosciences Reports First Quarter 2024 Financial Results and Recent Highlights
Clinical trial application clearances received for a Phase 1a/1b trial for ABI-5366 targeting recurrent genital herpes, and a Phase 1b trial for ABI-4334 in chronic HBV infection; both studies on track to initiate by mid-2024 ABI-5366 interim Phase 1a first-in-human data expected in Q3 2024 and ABI-4334 interim Phase 1b data expected by end of year SOUTH SAN FRANCISCO, Calif., May 08, 2024 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a biotechnology company developing innovativ
